Hansa Biopharma AB, which appointed a new CEO and COO earlier this year, has announced plans to restructure its organization to optimize resource allocation and improve operational efficiency. The planned restructuring would result in an approximately 20% reduction in the current workforce and would result in projected annual savings of 40-50 million Swedish krona. The restructuring is subject to negotiation with relevant trade unions. Renée Aguiar-Lucander, CEO, Hansa Biopharma said: “This p...